[New Data!] Etrasimod in IBD Mouse Models
We are excited to share new efficacy data for Etrasimod (VELSIPITY) in inflammatory bowel disease (IBD) mouse models.
Etrasimod, a sphingosine 1-phosphate (S1P) receptor modulator, was approved on October 12, 2023, as an oral treatment for ulcerative colitis.
Building on our previous efficacy data for Mesalazine and Tacrolimus in IBD models, we have now successfully evaluated Etrasimod’s potential. Building on our previous efficacy studies with mesalazine and tacrolimus in IBD models, we have now obtained promising results with Etrasimod.
In this study, we evaluated the intestinal fibrosis that occurs after the onset of IBD, and we observed a significant improvement in fibrosis in the Etrasimod treatment group.
If you’re interested in further details about the IBD model data or additional results from the Etrasimod study, please don’t hesitate to reach out.
We have conducted more than 1,000 drug efficacy studies and our IBD mouse models have become the preferred choice for evaluating both inflammation and fibrosis across various disease stages in intestine. By incorporating Etrasimod as a control, we aim to enhance the precision and relevance of your research.